[go: up one dir, main page]

DK1536015T3 - Promotorer til ekspression i modificeret vacciniavirus Ankara - Google Patents

Promotorer til ekspression i modificeret vacciniavirus Ankara

Info

Publication number
DK1536015T3
DK1536015T3 DK04000943T DK04000943T DK1536015T3 DK 1536015 T3 DK1536015 T3 DK 1536015T3 DK 04000943 T DK04000943 T DK 04000943T DK 04000943 T DK04000943 T DK 04000943T DK 1536015 T3 DK1536015 T3 DK 1536015T3
Authority
DK
Denmark
Prior art keywords
expression
promoters
vaccinia virus
virus ankara
modified vaccinia
Prior art date
Application number
DK04000943T
Other languages
Danish (da)
English (en)
Inventor
Sonja Dr Leyrer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK1536015T3 publication Critical patent/DK1536015T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • A61K39/285Vaccinia virus or variola virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK04000943T 2003-11-24 2004-01-17 Promotorer til ekspression i modificeret vacciniavirus Ankara DK1536015T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200301730 2003-11-24

Publications (1)

Publication Number Publication Date
DK1536015T3 true DK1536015T3 (da) 2008-02-18

Family

ID=34442836

Family Applications (3)

Application Number Title Priority Date Filing Date
DK07014231.0T DK1845164T3 (da) 2003-11-24 2004-01-17 Promoterer til ekspression i modificeret vacciniavirus ankara
DK04000943T DK1536015T3 (da) 2003-11-24 2004-01-17 Promotorer til ekspression i modificeret vacciniavirus Ankara
DK04790902T DK1689872T3 (da) 2003-11-24 2004-10-27 Promotorer til ekspression i modificeret vacciniavirus Ankara

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK07014231.0T DK1845164T3 (da) 2003-11-24 2004-01-17 Promoterer til ekspression i modificeret vacciniavirus ankara

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04790902T DK1689872T3 (da) 2003-11-24 2004-10-27 Promotorer til ekspression i modificeret vacciniavirus Ankara

Country Status (18)

Country Link
US (3) US7816508B2 (fr)
EP (4) EP1536015B1 (fr)
JP (2) JP2007512009A (fr)
KR (1) KR20060109873A (fr)
CN (1) CN1898390A (fr)
AT (4) ATE471383T1 (fr)
AU (1) AU2004295382A1 (fr)
BR (1) BRPI0416916A (fr)
CA (1) CA2546680A1 (fr)
DE (4) DE602004027767D1 (fr)
DK (3) DK1845164T3 (fr)
EA (1) EA012846B1 (fr)
IL (4) IL174653A0 (fr)
NO (1) NO20062948L (fr)
NZ (1) NZ547405A (fr)
SG (2) SG169325A1 (fr)
UA (1) UA90098C2 (fr)
WO (1) WO2005054484A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA76731C2 (uk) * 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
DE602004027767D1 (de) * 2003-11-24 2010-07-29 Bavarian Nordic As Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
EP2042604A1 (fr) * 2007-09-26 2009-04-01 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Surexpression commandée par promoteur VV d'antigènes recombinants
EP2367944B1 (fr) * 2008-11-27 2019-01-09 Bavarian Nordic A/S Promoteurs pour expression virale recombinante
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
AU2011316164B2 (en) 2010-10-15 2016-01-14 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine
EP2788021B1 (fr) 2011-12-09 2017-01-18 Bavarian Nordic A/S Vecteur du poxvirus codant des antigènes bactériens lié à le fragment c de la toxine tétanique
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106754921A (zh) * 2016-12-12 2017-05-31 孙浩 哺乳动物细胞表达启动子及其制造和使用方法
US11242509B2 (en) * 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
IL322666A (en) 2023-03-17 2025-10-01 Helmholtz Zentrum M?Nchen Deutsches Forschungszentrum F?R Gesundheit Und Umwelt Gmbh A preparation containing HBV antigen for the treatment of hepatitis B
WO2025172435A1 (fr) 2024-02-13 2025-08-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Formulation d'antigène du vhb pour le traitement de l'hépatite b
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EE05633B1 (et) 2000-03-14 2013-02-15 Mayr Anton Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
UA76731C2 (uk) * 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
ES2334335T3 (es) * 2001-03-08 2010-03-09 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Mva que expresa genes de envoltura, gag y pol de vih modificados.
AU2003240243B2 (en) 2002-05-16 2009-01-22 Bavarian Nordic A/S Expression of genes in modified vaccinia virus Ankara by using the cowpox ATI promoter
DE60336653D1 (de) * 2002-08-07 2011-05-19 Bavarian Nordic As Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren
DE602004027767D1 (de) * 2003-11-24 2010-07-29 Bavarian Nordic As Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara

Also Published As

Publication number Publication date
DE602004009743D1 (de) 2007-12-13
EP1689872A1 (fr) 2006-08-16
US7816508B2 (en) 2010-10-19
BRPI0416916A (pt) 2007-01-23
CN1898390A (zh) 2007-01-17
JP2007512009A (ja) 2007-05-17
NZ547405A (en) 2008-06-30
DE602004032187D1 (de) 2011-05-19
KR20060109873A (ko) 2006-10-23
EA200601043A1 (ru) 2006-10-27
EP1845164A3 (fr) 2008-03-19
EP1689872B1 (fr) 2009-01-07
DK1845164T3 (da) 2010-09-20
IL199127A (en) 2010-12-30
EP1956094A1 (fr) 2008-08-13
IL199128A (en) 2011-03-31
ATE471383T1 (de) 2010-07-15
SG169325A1 (en) 2011-03-30
US20110014242A1 (en) 2011-01-20
IL199126A (en) 2010-12-30
SG142300A1 (en) 2008-05-28
ATE420191T1 (de) 2009-01-15
DK1689872T3 (da) 2009-04-27
AU2004295382A1 (en) 2005-06-16
IL174653A0 (en) 2006-08-20
ATE504654T1 (de) 2011-04-15
UA90098C2 (en) 2010-04-12
EP1536015A1 (fr) 2005-06-01
WO2005054484A1 (fr) 2005-06-16
DE602004027767D1 (de) 2010-07-29
EP1845164A2 (fr) 2007-10-17
EP1845164B1 (fr) 2010-06-16
EA012846B1 (ru) 2009-12-30
EP1956094B1 (fr) 2011-04-06
JP2011067219A (ja) 2011-04-07
ATE377088T1 (de) 2007-11-15
EP1536015B1 (fr) 2007-10-31
US20110008792A1 (en) 2011-01-13
US20080112971A1 (en) 2008-05-15
NO20062948L (no) 2006-08-23
CA2546680A1 (fr) 2005-06-16
DE602004018975D1 (de) 2009-02-26
DE602004009743T2 (de) 2008-08-28

Similar Documents

Publication Publication Date Title
IL199127A (en) Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters
ATE490262T1 (de) Abschwächung der immunogenizität von fusionsproteinen
IL182357A0 (en) Malaria prime/boost vaccines
DK1282702T3 (da) Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
DK1685247T3 (da) Vektorer til retningsbestemt kloning
UA82998C2 (ru) Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
DK1618128T3 (da) Tuberkulosevaccine med forbedret effektivitet
DK1675956T3 (da) Minimal DNA-sekvens, der virksom som chromatinisolator, og dennes anvendelse til proteinekspression
CY1109244T1 (el) Νευρολοιμογονο στελεχος του ιου δυτικου νειλου και εφαρμογες αυτου.
ATE532861T1 (de) Expressionsvektor
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
IL164179A0 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
MX2022015489A (es) Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
WO2005011571A3 (fr) Proteines du noyau du virus de l'hepatite utilisees comme plateformes de vaccins et leur utilisation
BRPI0516576A (pt) vetores quiméricos
NO20063521L (no) Blandinger, fremgangsmater og anvendelser av en ny peptidfamilie
DE50312368D1 (de) Rekombinante mva-stamme als potentielle impfstoffe gegen p. falciparum -malaria
ATE493146T1 (de) Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
WO2004087886A3 (fr) Constructions adenovirales e1a modifiees et procedes d'utilisation
WO2005001096A8 (fr) Vaccins contre le sras
ATE547530T1 (de) Rekombinante vektoren auf der grundlage des modifizierten vacciniavirus ankara (mva) als impfstoffe gegen leishmaniase
WO2005094415A3 (fr) Vecteurs recombinants et methodes pour induire une reponse immunitaire